DUBLIN--(BUSINESS WIRE)--The "Global Bacterial Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
The Global Bacterial Partnering 2012-2018: Deal trends, players and financials report provides an understanding and access to the Bacterial partnering deals and agreements entered into by the world's leading healthcare companies.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Bacterial disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Bacterial deals.
The report presents financial deal terms values for Bacterial deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
- Trends in Bacterial dealmaking in the biopharma industry since 2012
- Analysis of Bacterial deal structure
- Access to headline, upfront, milestone and royalty data
- The leading Bacterial deals by value since 2012
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Bacterial dealmaking
Chapter 3 - Financial deal terms for Bacterial partnering
Chapter 4 - Leading Bacterial deals and dealmakers
Chapter 5 - Bacterial contract document directory
Chapter 6 - Bacterial dealmaking by therapeutic target
